SparingVision

Genomic medicine company developing vision-saving treatments for ocular diseases #vision #blindness #genetherapy #biotech #healthtech

[SparingVision @SparingVision]

We are pleased to share that we have received FDA IND clearance for SPVN20, our gene-agnostic program aiming to restore vision for people with IRDs. We look forward to sharing updates on the clinical development progress 🎉.
#OcularDisease #Ophthalmology

[SparingVision @SparingVision]

@SparingVision will be at #Jefferies in London, November 16–19.
@BoisselStephane, CEO, Kali Stasi, CMO, and Mehdi Gasmi, CSO & CTO, look forward to connecting with investors and industry peers.
👉 Interested in meeting our team? Get in touch to arrange a meeting!
#GeneTherapy

[SparingVision @SparingVision]

🇺🇸 Heading to Boston and New York!
Our CEO, Stéphane Boissel, will attend the Guggenheim and Stifel Healthcare Conferences next week.
Looking forward to connecting with peers and investors at both conferences.
👉If you’re attending, we would be happy to connect!

[SparingVision @SparingVision]

Looking forward to RHO Day on November 6!
Our CMO, Kali Stasi, will share SparingVision’s approach to preserving and restoring vision for people living with inherited retinal diseases.
👉 Learn more: https://t.co/6pAdAiZGi9
#RHODay #InheritedRetinalDiseases

[SparingVision @SparingVision]

🇩🇪 Hallo Hamburg!
Our Head of Manufacturing Pierre-Axel Vinot and our Senior Director Analytical Sciences Fabien Dorange will be at #ESGCT2026 in Hamburg!
🤝 You’re attending too? Don’t hesitate to connect with them!
#GeneTherapy #Biotech

[SparingVision @SparingVision]

Hallo Utrecht! 🇳🇱 Marie & Pauline from our regulatory team are at #TOPRASymposium2026. 🎤 Marie will chair SME4 tomorrow at 11 AM. Let's connect! 🤝 #RegulatoryAffairs #Biotech

[SparingVision @SparingVision]

Over the past two weeks, our CMO Kali Stasi attended #EURETINA2026 in Vienna and @aao_ophth in New Orleans, connecting with retina specialists, ophthalmologists, researchers and partners.
Thank you to all who took the time to connect.
#Ophthalmology #GeneTherapy

[SparingVision @SparingVision]

This week, our team will be in Florence at the 29th EVER Congress, from 15-17 October. We look forward to connecting with experts in the field and sharing clinical updates on our gene-agnostic programs.

#GenomicMedicine #Ophthalmology #OcularDisease

[SparingVision @SparingVision]

Today, we're standing with patients on #WorldSightDay.

We’re developing gene-agnostic gene therapies with the goal to preserve, protect, and enhance visual function and slow blinding retinal diseases.
Learn more: https://t.co/uyyfp3YEwE

[SparingVision @SparingVision]

Next month, our team is looking forward to attending various conferences in the US and across Europe, sharing updates on our gene agnostic portfolio. See where we’ll be below👇

#GenomicMedicine #Ophthalmology #OcularDisease

[SparingVision @SparingVision]

Meet Jérôme Maes, Head of Program Management at SparingVision, driving our gene-agnostic gene therapy programs from concept to patients — with the chance to restore vision for those with inherited retinal diseases. https://t.co/bSjzy01evm #EmployeeSpotlight

[SparingVision @SparingVision]

🔬 Patients are at the heart of what we do.
From engaging with the patient community at the @RETINAFRANCE conference in Agde to hearing a patient’s personal journey during our annual offsite, these exchanges remind us why our work matters. 💙

[SparingVision @SparingVision]

After a busy H1 2026 at conferences worldwide, SparingVision looks forward to connecting with the retinal, gene therapy, and investor communities in the next half of 2026. We'll be sharing updates on SPVN06 and SPVN20, our #gene-agnostic programs for retinal diseases.
#Conference

[SparingVision @SparingVision]

Excited to see our CEO Stéphane Boissel featured in @BioCentury 's article looking at the future of RP treatment.

Read the full piece here: https://t.co/ANdexH1mAY

#GenomeEditing #GenomicMedicines #Ophthalmology #GeneTherapy

[SparingVision @SparingVision]

Earlier this month, the SparingVision team enjoyed some time together at our summer offsite. A special thank you to @RETINAFRANCE for joining us and sharing valuable patient perspectives.
#GenomicMedicines

[SparingVision @SparingVision]

We are pleased to announce FDA Fast Track designation for our gene agnostic gene therapy SPVN06 in retinitis pigmentosa, highlighting a high unmet medical need and enabling closer FDA interactions to accelerate development. For more information : https://t.co/91hVfAccdd

[SparingVision @SparingVision]

Great month for the SparingVision team at @ARVOinfo. Our CMO, Kali Stasi, joined discussions on retinal innovation, #GeneTherapy, and ocular AAVs for IRDs, plus Prof. Jose-Alain Sahel’s Proctor Award Lecture. Image credit: The Eye & Ear Foundation of Pittsburgh.

[SparingVision @SparingVision]

🌟Last week, Pierre Axel Vinot, our Senior Director, CMC Portfolio Management, attended #ASGCT in Boston. He presented 2 posters with Genezen.
Thanks to ASGCT for inspiring discussions, we are already looking forward to next year!
#ASGCT #GeneTherapy #Biotech

[SparingVision @SparingVision]

🌟We are incredibly proud of our co-founder, Dr. José‑Alain Sahel, honored with the 2026 ARVO Proctor Medal. A well‑deserved honor celebrating decades of breakthrough retinal research and impact for patients. #ARVO #ProctorMedal.

[SparingVision @SparingVision]

Our CMO Kali Stasi will be at the ARVO annual meeting, the leading global event in ophthalmology and vision research.
📍May 3–7, Denver, CO
👋Feel free to reach out if you’d like to connect! #ARVO2026 #Ophthalmology #Innovation